Certificate of analysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-19. Numbers and descriptions here follow the published literature rather than marketing material.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
| Property | Value | Notes |
|---|---|---|
| Primary research models | Rodent studies | Largest share of published data |
| Reported markers | BDNF and NGF expression | Measured mainly in animal tissue |
| Common administration | Intranasal | Matches the registered formulation |
| Blood residence time | Minutes | Rapid enzymatic degradation |
| Evidence quality | Small trials, limited replication | Noted repeatedly in reviews |
Material sold for laboratory use varies widely in stated purity and documentation. A certificate of analysis should list the analytical method, the column and detector used, and the observed purity value. Independent verification by an outside laboratory is the practical way to confirm identity when documentation is absent or internally inconsistent. Regulatory status differs by country, and a product legal in one jurisdiction may be unapproved or controlled in another.
Identity and purity of semax are established with reversed-phase high-performance liquid chromatography coupled to ultraviolet detection, usually at 214 nanometres. Mass spectrometry, most often electrospray ionisation in positive mode, confirms the molecular mass and reveals truncated sequences. Amino acid analysis and peptide mapping after enzymatic digestion provide additional structural confirmation. Laboratories typically report purity as the percentage area of the main peak, a figure that does not capture isomeric or oxidised variants unless the method resolves them.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
=== Cellular uptake === Fluoroquinolones can enter in cells easily via porins, so are often used to treat intracellular pathogens such as Legionella pneumophila and Mycoplasma pneumoniae. For many Gram-negative bacteria, DNA gyrase is the target, whereas topoisomerase IV is the target for many Gram-positive bacteria. Eukaryotic cells are not believed to contain DNA gyrase or topoisomerase IV. However, debate exists concerning whether the quinolones still have such an adverse effect on the DNA of healthy cells. Some compounds in this class have been shown to inhibit the synthesis of mitochondrial DNA.
Amaninamide is a cyclic peptide. It is one of the amatoxins, all of which are found in several members of the mushroom genera Amanita, Lepiota and Galerina. It differs from alpha-amanitin in lacking the hydroxyl group on tryptophan. This alters its UV absorption spectrum but not its toxicity.
MAL-LAD, or MALLAD, also known as METAL-LAD or METALLAD, as well as 6-methallyl-6-nor-LSD, is a serotonin receptor modulator of the lysergamide family related to lysergic acid diethylamide (LSD). The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor among others. It is also a dopamine receptor agonist, though unlike other lysergamides, does not show activity at the dopamine D1 and D5 receptors. MAL-LAD does not appear to have been assessed in animal tests of psychedelic-like activity such as drug discrimination. MAL-LAD was first described in the scientific literature by Andrew Joseph Hoffman of the lab of David E. Nichols at Purdue University by 1987. It was subsequently further described by a group of researchers that included Nichols and other colleagues in 2025. The drug is not a controlled substance in Canada as of 2025.
Systematic doping in Russian sports has resulted in 47 Olympic and tens of world championships medals being stripped from Russian competitors—the most of any country, more than four times the number of the runner-up, and more than 30% of the global total. Russia also has the most competitors that have been caught doping at the Olympic Games, with more than 200. Russian doping is distinct from doping in other countries because in Russia the state supplied steroids and other drugs to sportspeople. Due to widespread doping violations, including an attempt to sabotage ongoing investigations by the manipulation of computer data, on 9 December 2019 the World Anti-Doping Agency (WADA) banned Russia from all international sport for four years. As at the 2018 Winter Olympics, WADA will allow individual cleared Russian athletes to compete neutrally under a title to be determined (which may not include the name "Russia", unlike the use of "Olympic Athletes from Russia" in 2018). Russia later filed an appeal to the Court of Arbitration for Sport (CAS) against the WADA decision. The Court of Arbitration for Sport, on review of Russia's appeal of its case from WADA, ruled on 17 December 2020 to reduce the penalty that WADA had imposed. Instead of banning Russia from sporting events, the ruling allowed Russia to participate at the Olympics and other international events, but for a period of two years the team cannot use the Russian name, flag, or anthem and must present themselves as "Neutral Athlete" or "Neutral Team".
=== Chemicals and semiconductors === Ajinomoto has developed mild cleansing agents such as Amisoft and Amilite, and humectant emollients such as Eldew and Amihop. It also manufactures for companies such as Daiichi Sankyo Healthcare Co., Ltd. to develop products like the moisturizing detergent Minon. Ajinomoto developed its resin functional materials business using technology obtained through the production of MSG. Ajinomoto developed the Ajinomoto build-up film (ABF) substrate for insulating materials in semiconductor packages in high-performance CPUs. It was developed from the basic research on applications of amino acid chemistry to epoxy resins and their composites. ABF holds 90% of the market for this product.
Sources: en.wikipedia.org
== Method translation == Faster GC methods have shorter times but Kovats indices of the compounds may be conserved if proper method translation is applied. Temperatures of the temperature program stay the same, but ramps and times change when using a smaller column or faster carrier gas. If column dimensions Length×diameter×film are divided by 2 and gas velocity is doubled by using H2 in place of Helium, the hold times must be divided by 4 and the ramps must be multiplied by 4 to keep the same index and the same retention temperature for the same compound analyzed. Method translation rules are incorporated in some chromatography data systems.
== Academic achievements == Dr. Goldstein is the author of more than 450 scientific articles in professional journals, the inventor on over 25 U.S. and worldwide patents, and the editor of several books and monographs in the fields of biochemistry, biomedicine, immunology and neuroscience. Over the years, Dr. Goldstein's laboratory has been a center for the training of graduate, medical, and postdoctoral students, many of whom are now continuing and expanding his studies on the role of the thymus in health and disease. Dr. Goldstein has also been a pioneer in medical education, having developed a unique series of distance-education programs presented on the Internet entitled Frontiers in Medicine. This series of lectures and national town forums by leading scientists focused on cutting-edge research. The broadcasts, which were presented live from George Washington University, began in 1997 and were a first for continuing medical education on the Internet. Frontiers in Medicine received the FREDDIE award for best health site at the 1997 American Medical Association Health and Medicine film competition in San Francisco.
=== Europe === The U.S. market is being eclipsed by booming demand for cocaine in Europe, where users now pay twice the going U.S. rate. In 2008, U.S. Attorney General Michael Mukasey announced that an international drug interdiction operation, Project Reckoning, involving law enforcement in the United States, Italy, Canada, Mexico and Guatemala had netted more than 500 organized crime members involved in the cocaine trade. The announcement highlighted the Italian-Mexican cocaine connection. Concerns about European security and the trafficking of drugs through the European continent have grown in recent years, and, in December 2022, Europol and the DEA released a joint report on the situation involving Mexican drug trafficking through the EU. In December 2011, the government of Spain remarked that Mexican cartels had multiplied their operations in that country, becoming the main entry point of cocaine into Europe. In 2012, it was reported that Mexican cartels had joined forces with the Sicilian Mafia, when Italian officials unearthed information that Palermo's black market, along with other Italian ports, was used by Mexico's drug cartels as a conduit to bring drugs to the European market, in which they had been trafficking drugs, particularly cocaine, throughout the Atlantic Ocean for over ten years to Europe.
Alexander Alexeyevich Makarov, (Russian: Александр Алексеевич Макаров; born 1966) is a Russian physicist who led the team that developed the Orbitrap, a type of mass spectrometer, and received the 2008 American Society for Mass Spectrometry Distinguished Contribution in Mass Spectrometry Award for this development. In November 2013 he was appointed to Professor by Special Appointment of High Resolution Mass Spectrometry at the Department of Chemistry and the Bijvoet Center for Biomolecular Research of Utrecht University in the Netherlands. As of 2016, he is Director of Global Research for Life Sciences Mass Spectrometry at Thermo Fisher Scientific.
Food and Agriculture Organization (FAO) Codex Alimentarius (a commission of the United Nations) US Food and Drug Administration (FDA) European Union World Health Organization (WHO) There are seven basic principles:
Sources: en.wikipedia.org
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.
The compound is registered as a medicine in Russia, so clinical work has concentrated there. Trials elsewhere are few and generally small. This geographic concentration is a recognized limitation in evidence reviews.
Some fraction may reach the central nervous system through olfactory pathways, and this is often cited as the rationale for the nasal route. The size of that fraction in humans is not well quantified. Blood concentrations after nasal dosing are low, which complicates measurement.
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.